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Abstract
Objectives—Ginger is one of the most commonly used herbal medicine for Irritable Bowel
Syndrome (IBS) but no data exists about its effectiveness.
Design—Double blind randomized controlled trial
Setting—University of North Carolina, Chapel Hill North Carolina, USA
Intervention—Forty-five IBS patients were randomly assigned to three groups: placebo, one
gram of ginger, and two grams of ginger daily for 28 days.
Main outcome measures—The IBS severity scale (IBS-SS) was administered, as well as
adequate relief of symptoms scale. A responder was defined as having at least 25% reduction in
IBS-SS post-treatment.
Results—There were 57.1% responders to placebo, 46.7% to one gram and 33.3% to two grams
of ginger. Adequate relief was reported by 53.3% on placebo and 53.3% in both ginger groups
combined. Side effects were mild and reported by 35.7% in the placebo and 16.7% in the ginger
groups.
Conclusions—This double blind randomized controlled pilot study suggests ginger is well
tolerated but did not perform better than placebo. Larger trials are needed before any definitive
conclusions can be drawn.
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Introduction
Irritable Bowel Syndrome (IBS) is a common chronic condition consisting of abdominal
pain with changes in bowel habits. The effectiveness of treatments for IBS are limited and
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about 40% of patients use alternative medicine to treat their symptoms1. The most popular
alternative medicine in a large study of 600 IBS patients was ginger1.
Ginger root is the rhizome of the perennial plant Zingiber Officinalis Roscoe. Ginger
contains 1–3% of oils. Ginger dosing is often standardized according to gingerol content
which is assumed to have antiemetic, analgesic, sedative, antibacterial and other
physiological effects though other non-volatiles may have some of the same effects2–4.
Ginger is on the American Food and Drug Administration Generally Recognized as Safe list
meaning that it is considered safe and is exempted from premarket review, approval, and
clinical testing before marketing (http://www.fda.gov/Food/IngredientsPackagingLabeling/
GRAS/ucm2006850.htm).
There is some evidence to suggest that ginger can affect IBS symptoms. In Micromedex (an
evidence based clinical reference tool for hospitals and physicians; www.micromedex.com)
ginger is classified as a broad spectrum antiemetic, and is effective in treating nausea and
vomiting associated with pregnancy5 and surgery6. Ginger has also been found to influence
pain and gut motility2, 4. Thus, ginger may be useful in reducing both pain and stool changes
in IBS.
Given the known gastrointestinal effects of ginger, its common use among IBS patients and
its wide availability and low cost, ginger should be tested as a potential treatment for IBS.
The goal of this pilot study was to test the effects of ginger on IBS symptoms through a
randomized placebo and dose dependent controlled trial. We chose to run a pilot study to
look for signal and magnitude of clinical effect to support the rational and direct the design
of a larger study
Methods
Subjects
Subjects were 45 patients age 18 and older with a physician diagnosis of Irritable Bowel
Syndrome (IBS) verified by Rome III criteria. Patients were identified by sending a mass e-
mail to all students, staff, and faculty at the University of North Carolina. All participants
needed to have symptoms at least once a week severe enough to interfere with daily
activities and report being on a stable dose of current medications for IBS for at least 4
weeks. Subjects were excluded if they reported: (a) regular use of ginger (b) ginger allergy/
intolerance, (c) history of surgical resection of part of the gastrointestinal tract, (d) being
pregnant or planning to become pregnant, or (e) use of cardiotonic or diabetic medications
contra-indicated for use with ginger.
The study employed a randomized, controlled, parallel group design in which 15 subjects
were randomly assigned to each of three arms: placebo, one gram ginger daily, or two grams
ginger daily. Treatment duration was 28 days. Most previous trials of gastrointestinal related
symptoms, such as nausea/vomiting associated with cancer or pregnancy, have used similar
1–2 grams daily doses5, 7. Given that no previous studies have tested the use of ginger in
IBS patients, we have no information to guide power analyses for a trial. Therefore, we
chose to run an initial trial with 15 subjects in each arm to look for signal and magnitude of
clinical effect to support the rational and direct the design of a larger study.
Study design
All patients completed consent, screening and baseline questionnaires online. More patients
expressed interest in participation than the required 45 – only the first 45 were invited to
participate. Upon randomization (by a perl-based computer program), a one month supply of
ginger or placebo capsules was sent by mail. Packages included instructions on starting and
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stopping dates. Patients were contacted within 24 hours of ingesting first capsule, and
biweekly thereafter to check for compliance and side effects. The study was approved by the
Institutional Review Board of the University of North Carolina (approval# 07-1035).
Ginger and placebo capsules
The ginger and placebo capsules were blister packed to ensure blinding8, by a compounding
pharmacy. The pharmaceutical grade ginger contained 2.29 mg/g of gingerols and 6-
shogaols. The placebo contained brown sugar. The pharmacy coded the capsules for
blinding and sent a coding key via mail at study completion.
Measures
Irritable Bowel Syndrome Severity Scale (IBS-SS)—The IBS-SS 9 measures IBS
severity with five items (severity and frequency of pain, abdominal distension, bowel
dissatisfaction, and interference with life) rated on a 0–100 scale. A responder was defined
as at least a 25% reduction in IBS-SS scores post-treatment.
Adequate Relief Rating Scale (ARRS)—At the end of treatment, patients were asked
to respond to the question, “In the last week, have you had adequate relief of your
abdominal pain and other symptoms of IBS (yes or no)?”10.
Data analyses
Paired t-test were run to compare IBS severity scores before and after treatment. Percentage
of responders and ARRS was compared across the three treatment arms with Chi2 tests.
Results
One-hundred-eighty-one interested patients responded to study notices and completed
screening. Of this group the first 45 eligible patients were invited to participate (see Figure 1
for a CONSORT diagram). No differences between the 3 treatment arms were found in
gender, age and IBS-SS scores at baseline. Treatment compliance was acceptable: 97.3% in
the placebo group, 98.5% in the 1 gram ginger group, and 85.2% in the 2 gram ginger group.
Side effects were mild and reported by 35.7% in the placebo and 16.7% in the ginger
groups. Except for two subjects who reported headaches and tiredness, all side effects were
gastrointestinal symptoms including heart-burn, nausea, difficulty passing stool, more
frequent stools, loose stools, bloating and hunger suppression.
IBS severity scores before and after treatment are given in Table 1. Placebo and 1 gram
ginger groups saw a significant reduction in symptoms by 34.8% and 26.4% respectively.
Number of treatment responders across groups was not different (57.1% placebo, 46.7% 1 gr
ginger, 33.3% 2 grams ginger; p>.05). Adequate relief was reported by 53.3% in the placebo
group and 53.3% in both the ginger groups (p>.05).
Discussion
Ginger is one of the most commonly used herbal medicines by IBS patients1. This is the first
study to date that examines the effectiveness of ginger in IBS. Since this is a pilot study, it
may not be powered to find significant results. Therefore, we examined trends in the effects
of ginger that would suggest ginger might be an effective treatment in a larger trial. Instead,
we found a trend for IBS symptoms to improve more with placebo than ginger.
This study had several strengths including the randomized controlled design, the use of
pharmaceutical grade ginger with known gingerol content, and assuring blinding of study
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participants by using blister packs. However, the study also had several limitations,
including the small sample size, the short treatment duration, recruitment among university
employees and students as well as the absence of blinding of investigators during the
analysis phase of the study. These limit our ability to generalize and draw any definitive
conclusions about the effects of ginger on IBS. Larger trials of longer duration are needed.
The placebo effect is known to be strong in studies on treatment response in IBS patients.
On average a 40% placebo response has been found in IBS trials11. Our placebo response
was considerably higher at 57%. The placebo group also reported twice as many side effects
as the ginger group, corroborating the placebo effect. The placebo effect includes a
regression to the mean, natural history of the disease as well as treatment expectancies.
Treatment expectancies can be raised by verbal and non-verbal cues12 of which many will
be delivered within the clinic setting and direct patient-physician interactions. We
minimized most of these factors by having no participants visit a clinic, no face-to-face
contact with the researchers, and taking efforts to assure blinding (by using blister packs to
conceal smell and providing color and texture of placebo comparable to ginger). Most other
IBS treatment trials have not minimized or manipulated the placebo response11.
However, the placebo effect is influenced by many factors some of which are not always
obvious. For example, patients do not have to be blinded to display a strong placebo effect if
the right cues are provided. Kaptchuk and colleagues showed that an open label inactive
placebo pill produced better outcomes in IBS patients compared to no treatment13. In
Kaptchuk’s study the placebo was introduced as powerful, having a conditioned effect on
the body, and becoming stronger with a positive attitude. These instructions may have
increased the likelihood of a positive response to placebo. Although we took measures to
blind our participants and minimize nonspecific placebo effects within patient-clinician
interactions, we may have raised treatment expectancies by informing potential subjects in
the consent form that many IBS patients use ginger to treat symptoms, ginger can have
effects on pain and motility, and ginger may be a potential new treatment for IBS. Thus, we
may have generated a placebo response with the information we provided to the subjects.
Future studies are needed to examine context and cues in treatment trials of ginger.
Previous studies have shown that ginger effectively treats gastrointestinal symptoms, has
antiemetic as well as pain relieving effects, and is one of the most widely used herbal
medicines by IBS patients1, 2, 4–7. These observations suggest a role of ginger in the
treatment of IBS. The current study does not support this, but is in need of replication.
Ginger’s placebo response needs to be accounted for when designing future clinical trials.
Investigators should pay attention to cues and suggestions of the efficacy of ginger in IBS.
Kaptchuk and colleagues13 suggests that recommending a placebo may be reasonable for
certain disorders such as IBS, if carefully monitored by the physician. Whether or not ginger
may prove to be effective for IBS in future trials, in the light of Kaptchuk and collegues’
comments, clinicians may choose to be supportive of the use of ginger in patients who report
adequate relief with this treatment while informing the patient about possible interactions
with other medications and side effects.
There are additional issues, which will need to be addressed in future studies. Given ginger’s
prokinetic effect2 and efficacy in treating nausea5–7, ginger may be more effective for
certain subtypes of IBS or for those IBS patients who also complain of nausea or functional
dyspepsia. This emphasizes the need to explore the mechanisms by which ginger may affect
IBS symptoms – whether it is through anti-inflammatory, prokinetic, or other effects.
Mechanistic studies may give insight into the group of patients most likely to benefit from
treatment. Furthermore, although we used doses of ginger known to be effective for the
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treatment of nausea and vomiting, larger doses may be needed to reach efficacy in IBS.
Ginger is generally safe up to 6 grams daily, which may have a much larger effect.
Similarly, a different extract preparation with more concentrated gingerol content may also
provide higher response rates. One caveat is that in our small study the efficacy of ginger
decreased with larger doses. We observed a 26% decrease in symptoms with 1 gram versus
12% decrease in symptoms with 2 grams of ginger. Optimal ginger dosing will need to be
examined for future trials.
In summary, the current study does not find evidence for the use of ginger in treating IBS
but future larger trials are needed before any definitive conclusions can be drawn. The
considerable placebo response to ginger in this small group is in need of further exploration
and will have to be addressed in future trials of ginger.
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Placebo 253.2 (65.9) 165.0 (49.3) .001
1 gram ginger 260.0 (65.5) 191.3 (95.8) .007
2 grams ginger 222.7 (53.3) 198.9 (88.9) .233
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